In a Context of Critical Financial Situation, CARMAT Launches a Donation Campaign Open to All to Contribute to Its Funding and Continuation of Its Activities

Risk of insolvency as early as end of June 2025
Launch of a donation campaign open to all via the onparticipe.fr online platform
To listen to CARMAT CEO's message,click here
PARIS, June 20, 2025--(BUSINESS WIRE)--Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the "Company" or "CARMAT"), today announces the launch of a donation campaign open to all, to help fund its operations and continue its mission.
Critical financial situation and risk of insolvency at the end of June 2025
In a separate press release published today (see the press release), CARMAT announced that it is currently in a critical financial situation and facing a risk of insolvency as early as the end of June 2025.
The Company estimates its 12-month financial needs at approximately €35 million, including €3.5 million needed urgently before the end of June 2025, and an additional €4.5 million by the end of July 2025.
Despite efforts that are still ongoing, the Company has not yet been able to secure the financing required to continue its operations.
Launch of a donation campaign
Against this backdrop, and while continuing its efforts to raise funds, particularly through potential capital increases, CARMAT is today launching a donation campaign open to all. This initiative aims to allow individuals and organizations who support CARMAT's mission and wish to contribute to the continuity of its operations to do so.
Practical information on the donation campaign
The campaign opens on Friday, June 20, 2025.
Donations can only be made via the onparticipe.fr platform (available on this link). Should they experience issues, donors are invited to contact CARMAT at the following email address: donor@carmatsas.com
Main risks associated with donations
Potential donors' attention is drawn to the fact that donations made as part of this campaign are non-refundable and do not entail any equity stake in the Company. Donors will therefore not become creditors or shareholders of CARMAT through their donation.
Donors should also be aware that there is no guarantee that the donations received as part as this campaign, even in combination with any potential capital increases or other financing solutions that the Company could secure, will be sufficient to prevent a default at the end of June 2025 or beyond. As such, a default of the Company remains possible, even in the very short term.
Furthermore, donations made in the context of this campaign do not entitle donors to any tax benefits of any kind.
CARMAT, one of the most innovative French medtech companies in the world
A technological breakthrough: Aeson®, the world's first physiological artificial heart, to be both pulsatile, self-regulated, and highly hemocompatible
Increasing adoption by the medical community: over 120 patients treated worldwide, including more than 70 over the past 18 months
Recognition by experts worldwide: more than 60 hospitals trained across 17 countries
A team of around 180 highly skilled and committed people
Stéphane Piat, Chief Executive Officer of CARMAT, concludes: "After 30 years of research and with 120 patients treated, CARMAT's artificial heart is now the most advanced artificial heart in the world and the most credible solution to address the major challenge of advanced heart failure. This condition is currently the world's leading cause of death. As of today, heart transplantation remains the gold standard treatment, but human donor hearts are unfortunately not available in sufficient numbers, leaving thousands of patients without any solution every year.
CARMAT's heart is therefore absolutely essential to fight this growing health crisis and bring hope to patients and their families.
In order to continue its mission, CARMAT urgently needs €3.5 million by the end of June 2025, and approximately €35 million over the next 12 months. Failing that, we will most likely be forced to cease operations.
Despite our best efforts in a highly deteriorated environment, we have not yet been able to secure the financing required to continue our mission. This is why we are today calling on everyone's generosity to help CARMAT continue saving lives."
About CARMAT
CARMAT is a French MedTech that designs, manufactures and markets the Aeson® artificial heart. The Company's ambition is to make Aeson® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956).
For more information, please go to www.carmatsa.com and follow us on LinkedIn.
Name: CARMATISIN code: FR0010907956Ticker: ALCAR
Disclaimer
This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country.
This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the "AMF") under number D.25-0345 (the "2024 Universal Registration Document"), available free of charge on the websites of CARMAT (www.carmatsa.com/en/) and the AMF (www.amf-france.org).
Readers' attention is particularly drawn to the fact that the Company's current cash runway extends only until the end of June 2025, and that CARMAT is therefore facing a very high risk of default, including in the very short term. The Company is also exposed to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the progress and results of ongoing or planned clinical trials, technological developments, the competitive landscape, regulatory changes, industrial risks, and all risks related to the management of the Company's growth. Forward-looking statements mentioned in this press release may not be achieved due to these factors or other unknown risks and uncertainties, or risks that the Company does not currently consider to be material or specific.
Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250620686524/en/
Contacts
CARMAT Stéphane Piat Chief Executive Officer
Pascale d'Arbonneau Deputy Chief Executive Officer & Chief Financial OfficerTel.: +33 1 39 45 64 50contact@carmatsas.com
NewCap Press RelationsNicolas Merigeau Arthur Rouillé Tel.: +33 1 44 71 94 98carmat@newcap.eu
NewCap Financial Communication & Investor RelationsDusan Oresansky Jérémy Digel Tel.: +33 1 44 71 94 92carmat@newcap.eu

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

4 hours ago

• Yahoo

Dow Jones Futures: Will Elon Musk's Big Robotaxi Bet Pay Off? Four Stocks In Buy Areas

The market rally held in a range this past week, amid Israel-Iran news. The Tesla robotaxi launch is set for Sunday.

San Francisco Chronicle​

7 hours ago

• San Francisco Chronicle​

Florian Wirtz joins list of most expensive soccer signings in history

Florian Wirtz became one of the most expensive players in soccer history when the Germany playmaker joined Liverpool from Bayer Leverkusen on Friday for a fee of up to 116 million pounds ($156 million). Neymar: $262 million (222 million euros) Paris Saint-Germain shattered the world-record transfer fee by signing the Brazil superstar from Barcelona in August 2017. It was more than double the outlay of Manchester United to sign Paul Pogba from Juventus for $116 million a year earlier. It remains the record transfer fee. ___ Kylian Mbappé: $216 million (180 million euros) A few weeks after buying Neymar, PSG also secured a loan deal for Mbappé — then the rising star of French soccer playing for Monaco — that included the option to make the move permanent in 2018. PSG did so, making it an outlay of nearly $500 million on two players. ___ Flush with cash after selling Neymar a year earlier, Barcelona spent most of it in a deal to buy Brazil playmaker Coutinho from Liverpool for a Spanish record fee. ___ Moises Caicedo: $146 million (115 million pounds) The Ecuador midfielder's move was previously the most expensive deal by a British club, with Chelsea buying him from Brighton in August 2023. ___ João Félix: $140 million (126 million euros) Atletico Madrid triggered a buyout clause in Félix's contract to sign the Portugal forward from Benfica in August 2019. ___ Jude Bellingham: $139 million (128.5 million euros) The England star got his big move to Real Madrid from Borussia Dortmund in June 2023, for an initial up-front fee of 103 million euros plus add-ons linked to performance. ___ Antoine Griezmann: $134 million (120 million euros) Atletico could afford to sign Félix after selling France forward Griezmann to Barcelona for a similar fee a few weeks earlier. ___ Neymar: $98 million (90 million euros) Outside from Europe, the biggest transfer deal also involved Neymar when he joined Al Hilal, a team in the Saudi Pro League, from Paris Saint-Germain in August 2023. That came at the height of Saudi Arabia's push to sign high-end soccer talent to ignite the oil-rich state's domestic league. ___

Business Wire

7 hours ago

• Business Wire

EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit